SAM
OCUL icon

Smartleaf Asset Management’s Ocular Therapeutix OCUL Stock Holding History

Smartleaf Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89K Hold
8,994
– – ﹤0.01% 1225
2026
Q1 		$66.6K Sell
8,994
-223
-2% -$2.13K ﹤0.01% 1313
2025
Q4 		$112K Buy
9,217
+8,434
+1,077% +$102K ﹤0.01% 1121
2025
Q3 		$9.81K Buy
783
+705
+904% +$8.43K ﹤0.01% 2114
2025
Q2 		$719 Sell
78
-148
-65% -$1.16K ﹤0.01% 2530
2025
Q1 		$1.71K Buy
+226
New +$1.74K ﹤0.01% 2501

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Smartleaf Asset Management's OCUL Position: Q2 2026 in Review

Smartleaf Asset Management held its Ocular Therapeutix (OCUL) position steady in Q2 2026 at 8,994 shares worth $89K. The position accounts for ﹤0.01% of the portfolio, ranked #1225.

Smartleaf Asset Management first reported a position in OCUL in Q1 2025 and has held it in 6 quarters since. The position peaked at $112K in Q4 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Smartleaf Asset Management held 8,994 shares of Ocular Therapeutix worth $89K as of Q2 2026.
  • Smartleaf Asset Management left its Ocular Therapeutix share count unchanged in Q2 2026.
  • Ocular Therapeutix made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #1225 holding.
  • Smartleaf Asset Management first reported a position in Ocular Therapeutix in Q1 2025 and has held it in 6 quarters since.
  • Smartleaf Asset Management's Ocular Therapeutix position peaked at $112K in Q4 2025.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.